Medical System Network (4350) · RiskRestated
Risk that changes in the consumption tax rate are not reflected in drug price standards
First written in FY2018. 2 of 3 entries say "Restated". Latest entry: FY2022.
3entries
5years
0from disclosures
How it moved
Same theme, other companies
Earnings impact on the dispensing business from consumption tax rate changes and differences in drug price pass-throughA theme 8 companies write about · 8 as a headwind · 0 as a tailwind
5 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「If the consumption tax rate is revised in the future and drug price standards do not move in line with the rate of change in the consumption tax rate, it may affect the performance of our group.」
The risk of an earnings impact from consumption tax rate revisions not being reflected in drug price standards continues. - FY2021RestatedAnnual report
「If the consumption tax rate is revised in the future and drug price standards do not move in line with the rate of change in the consumption tax rate, it may affect the performance of our group.」
The risk of an earnings impact from consumption tax rate revisions not being reflected in drug price standards continues to be described. - FY2018First statedAnnual report
「If the consumption tax rate is revised in the future and drug price standards do not move in line with the rate of change in the consumption tax rate, it may affect the performance of our group.」
Against the backdrop of a structure in which dispensing revenue is exempt from tax while pharmaceutical purchases are taxable, the risk that future consumption tax rate revisions will not be reflected in drug price standards is described.